B-Cell	0	10	Neutrophil	Neutrophil	NN	B-NP
O	11	19	function	function	NN	I-NP
O	20	22	in	in	IN	B-PP
B-Cancer	23	30	chronic	chronic	JJ	B-NP
I-Cancer	31	43	neutrophilic	neutrophilic	JJ	I-NP
I-Cancer	44	52	leukemia	leukemia	NN	I-NP
O	52	53	:	:	:	O
O	54	63	defective	defective	JJ	B-NP
B-Anatomical_system	64	75	respiratory	respiratory	JJ	I-NP
O	76	81	burst	burst	NN	I-NP
O	82	84	in	in	IN	B-PP
O	85	93	response	response	NN	I-PP
O	94	96	to	to	TO	I-PP
O	97	104	phorbol	phorbol	NN	B-NP
O	105	111	esters	ester	NNS	I-NP
O	111	112	.	.	.	O

O	113	123	Functional	Functional	JJ	B-NP
O	124	132	analyses	analysis	NNS	I-NP
O	133	137	were	be	VBD	B-VP
O	138	147	performed	perform	VBN	I-VP
O	148	150	on	on	IN	B-PP
B-Cell	151	162	neutrophils	neutrophil	NNS	B-NP
O	163	171	isolated	isolate	VBN	B-VP
O	172	176	from	from	IN	B-PP
O	177	178	6	6	CD	B-NP
O	179	187	patients	patient	NNS	I-NP
O	188	192	from	from	IN	B-PP
O	193	196	two	two	CD	B-NP
O	197	209	institutions	institution	NNS	I-NP
O	210	213	who	who	WP	B-NP
O	214	223	displayed	display	VBD	B-VP
O	224	232	features	feature	NNS	B-NP
O	233	235	of	of	IN	B-PP
B-Cancer	236	243	chronic	chronic	JJ	B-NP
I-Cancer	244	256	neutrophilic	neutrophilic	JJ	I-NP
I-Cancer	257	265	leukemia	leukemia	NN	I-NP
O	266	267	(	(	(	O
B-Cancer	267	270	CNL	CNL	NN	B-NP
O	270	271	)	)	)	O
O	271	272	.	.	.	O

O	273	278	These	These	DT	B-NP
B-Cell	279	290	neutrophils	neutrophil	NNS	I-NP
O	291	303	demonstrated	demonstrate	VBD	B-VP
O	304	305	a	a	DT	B-NP
O	306	316	consistent	consistent	JJ	I-NP
O	317	327	deficiency	deficiency	NN	I-NP
O	328	329	(	(	(	O
O	329	331	44	44	CD	B-NP
O	332	333	+	+	SYM	O
O	333	334	/	/	SYM	O
O	334	335	-	-	SYM	O
O	336	337	8	8	CD	B-NP
O	337	338	%	%	NN	I-NP
O	339	341	of	of	IN	B-PP
O	342	349	control	control	NN	B-NP
O	350	356	values	value	NNS	I-NP
O	356	357	)	)	)	O
O	358	360	in	in	IN	B-PP
O	361	371	superoxide	superoxide	NN	B-NP
O	372	377	anion	anion	NN	I-NP
O	378	379	(	(	(	O
O	379	381	O2	O2	NN	B-NP
O	381	382	-	-	HYPH	O
O	382	383	)	)	)	O
O	384	394	production	production	NN	B-NP
O	395	397	in	in	IN	B-PP
O	398	406	response	response	NN	B-NP
O	407	409	to	to	TO	B-PP
O	410	413	the	the	DT	B-NP
O	414	421	phorbol	phorbol	NN	I-NP
O	422	427	ester	ester	NN	I-NP
O	427	428	,	,	,	O
O	429	436	phorbol	phorbol	NN	B-NP
O	437	446	myristate	myristate	NN	I-NP
O	447	454	acetate	acetate	NN	I-NP
O	455	456	(	(	(	O
O	456	459	PMA	PMA	NN	B-NP
O	459	460	)	)	)	O
O	460	461	.	.	.	O

O	462	464	O2	O2	NN	B-NP
O	464	465	-	-	HYPH	I-NP
O	466	476	production	production	NN	I-NP
O	477	479	in	in	IN	B-PP
O	480	488	response	response	NN	B-NP
O	489	491	to	to	TO	B-PP
O	492	503	chemotactic	chemotactic	JJ	B-NP
O	504	512	peptides	peptide	NNS	I-NP
O	513	516	was	be	VBD	B-VP
O	517	521	near	near	IN	B-PP
O	522	528	normal	normal	JJ	B-ADJP
O	529	530	(	(	(	O
O	530	532	82	82	CD	B-NP
O	532	533	.	.	.	I-NP
O	533	534	3	3	CD	I-NP
O	535	536	+	+	SYM	B-NP
O	536	537	/	/	SYM	B-VP
O	537	538	-	-	SYM	B-NP
O	539	541	10	10	CD	B-NP
O	541	542	.	.	SYM	I-NP
O	542	543	7	7	CD	I-NP
O	543	544	%	%	NN	I-NP
O	545	547	of	of	IN	B-PP
O	548	555	control	control	NN	B-NP
O	556	562	values	value	NNS	I-NP
O	562	563	)	)	)	O
O	563	564	.	.	.	O

O	565	574	Bacterial	Bacterial	JJ	B-NP
O	575	582	killing	killing	NN	I-NP
O	583	586	was	be	VBD	B-VP
O	587	593	normal	normal	JJ	B-ADJP
O	594	596	in	in	IN	B-PP
O	597	600	the	the	DT	B-NP
O	601	604	two	two	CD	I-NP
O	605	613	patients	patient	NNS	I-NP
O	614	621	studied	study	VBN	B-VP
O	621	622	,	,	,	O
O	623	626	and	and	CC	O
O	627	637	chemotaxis	chemotaxis	NN	B-NP
O	638	641	was	be	VBD	B-VP
O	642	652	diminished	diminish	VBN	I-VP
O	653	655	in	in	IN	B-PP
O	656	664	response	response	NN	B-NP
O	665	667	to	to	TO	B-PP
O	668	675	zymosan	zymosan	NN	B-NP
O	675	676	-	-	HYPH	B-NP
O	676	685	activated	activate	VBN	I-NP
B-Organism_substance	686	692	plasma	plasma	NN	I-NP
O	693	696	and	and	CC	B-PP
O	697	699	to	to	TO	B-PP
O	700	704	high	high	JJ	B-NP
O	705	719	concentrations	concentration	NNS	I-NP
O	720	722	of	of	IN	B-PP
O	723	734	chemotactic	chemotactic	JJ	B-NP
O	735	743	peptides	peptide	NNS	I-NP
O	744	746	in	in	IN	B-PP
O	747	750	the	the	DT	B-NP
O	751	759	patients	patient	NNS	I-NP
O	760	767	studied	study	VBN	B-VP
O	767	768	.	.	.	O

O	769	778	Cytosolic	Cytosolic	JJ	B-NP
O	779	780	C	C	NN	I-NP
O	781	787	kinase	kinase	NN	I-NP
O	788	796	activity	activity	NN	I-NP
O	797	800	was	be	VBD	B-VP
O	801	810	decreased	decrease	VBN	I-VP
O	811	813	in	in	IN	B-PP
O	814	817	one	one	CD	B-NP
O	818	820	of	of	IN	B-PP
O	821	824	the	the	DT	B-NP
O	825	828	two	two	CD	I-NP
O	829	837	patients	patient	NNS	I-NP
O	838	845	studied	study	VBN	B-VP
O	845	846	.	.	.	O

O	847	852	These	These	DT	B-NP
O	853	860	results	result	NNS	I-NP
O	861	868	suggest	suggest	VBP	B-VP
O	869	873	that	that	IN	B-SBAR
O	874	875	a	a	DT	B-NP
O	876	885	deficient	deficient	JJ	I-NP
O	886	888	O2	O2	NN	I-NP
O	888	889	-	-	HYPH	B-NP
O	890	897	release	release	NN	I-NP
O	898	900	in	in	IN	B-PP
O	901	909	response	response	NN	B-NP
O	910	912	to	to	TO	B-PP
O	913	916	PMA	PMA	NN	B-NP
O	917	919	is	be	VBZ	B-VP
O	920	921	a	a	DT	B-NP
O	922	930	hallmark	hallmark	NN	I-NP
O	931	933	of	of	IN	B-PP
B-Cell	934	945	neutrophils	neutrophil	NNS	B-NP
O	946	948	in	in	IN	B-PP
B-Cancer	949	952	CNL	CNL	NNP	B-NP
O	953	956	and	and	CC	O
O	957	960	may	may	MD	B-VP
O	961	968	provide	provide	VB	I-VP
O	969	970	a	a	DT	B-NP
O	971	981	diagnostic	diagnostic	JJ	I-NP
O	982	991	indicator	indicator	NN	I-NP
O	992	994	of	of	IN	B-PP
O	995	999	this	this	DT	B-NP
O	1000	1009	condition	condition	NN	I-NP
O	1009	1010	.	.	.	O

